ArticleRenal failure2026
Clinicopathological features and outcomes of glomerular microangiopathy: a retrospective cohort study.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glomerular microangiopathy (GMA) is a group of diseases characterized pathologically by thrombotic microangiopathy (TMA) changes in the glomerulus without detectable microthrombi or intima edema of small arteries on renal biopsy. Few studies have focused on the clinicopathological characteristics and prognosis of patients with GMA. In this single-center retrospective cohort study, we summarized the clinical and pathological data of patients diagnosed with GMA between January 2005 and July 2023 at the Peking Union Medical College Hospital. Treatment and prognosis were also analyzed. A total of 32 patients diagnosed with GMA were included in this study. They were 62.5% male, with a mean age of 46 ± 17 years. The most common primary diseases were idiopathic multicenter Castleman disease (iMCD) (31.2%), POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes) syndrome (21.9%), and exposure to anti-vascular endothelial growth factor (VEGF) agents (21.9%). All the patients exhibited various degrees of proteinuria (2.22 g/d (IQR 0.94, 3.50)). Acute kidney injury (AKI) complicated by significantly elevated inflammatory markers was observed in 13 patients, mostly iMCD patients (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.